Understand the source comparison
Pinealon vs. Similar Peptides: Side Effect Comparison
Pinealon ERK 1/2 modulation, ROS reduction Unknown (limited data) Research only No human safety trials Cerebrolysin Neurotrophic factors Injection site reactions (15-20%) FDA-approved in some countries Extensive clinical safety data Noopept AMPA receptor modul
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Pinealon
- ERK 1/2 modulation, ROS reduction
- Unknown (limited data)
- Research only
- No human safety trials
- Cerebrolysin
- Neurotrophic factors
- Injection site reactions (15-20%)
- FDA-approved in some countries
- Extensive clinical safety data
- Noopept
- AMPA receptor modulation
- Headache (10-15%)
- Research/supplement
- Some human studies available
- BPC-157
- Growth factor modulation
- Minimal documented
- Extensive preclinical safety
- The comparison highlights Pinealon's unique position with extremely limited human safety data compared to related neuroprotective compounds.[1,2] While BPC-157 shares research-only status, it has more extensive preclinical safety documentation across multiple organ systems.